These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 23794672)

  • 1. Screening and risk evaluation for sudden cardiac death in ischaemic and non-ischaemic cardiomyopathy: results of the European Heart Rhythm Association survey.
    Proclemer A; Lewalter T; Bongiorni MG; Svendsen JH; Pison L; Lundqvist CB;
    Europace; 2013 Jul; 15(7):1059-62. PubMed ID: 23794672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How are European patients at risk of malignant arrhythmias or sudden cardiac death identified and informed about their risk profile: results of the European Heart Rhythm Association survey.
    Proclemer A; Bongiorni MG; Dagres N; Sciaraffia E; Todd D; Blomstrom-Lundqvist C;
    Europace; 2015 Jun; 17(6):994-8. PubMed ID: 26023178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of implantable cardioverter defibrillator and cardiac resynchronization therapy: an Italian survey study on 220 cardiology departments.
    Inama G; Pedrinazzi C; Landolina M; Oliva F; Senni M; Proclemer A; Berisso MZ; Pirelli S;
    J Cardiovasc Med (Hagerstown); 2012 Nov; 13(11):675-83. PubMed ID: 22002257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy.
    Disertori M; Quintarelli S; Mazzola S; Favalli V; Narula N; Arbustini E
    Europace; 2013 Dec; 15(12):1693-701. PubMed ID: 23946316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable cardioverter defibrillator use for primary prevention in ischaemic and non-ischaemic heart disease-indications in the post-DANISH trial era: results of the European Heart Rhythm Association survey.
    Haugaa KH; Tilz R; Boveda S; Dobreanu D; Sciaraffia E; Mansourati J; Papiashvili G; Dagres N
    Europace; 2017 Apr; 19(4):660-664. PubMed ID: 28431077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart rate turbulence predicts ICD-resistant mortality in ischaemic heart disease.
    Marynissen T; Floré V; Heidbuchel H; Nuyens D; Ector J; Willems R
    Europace; 2014 Jul; 16(7):1069-77. PubMed ID: 24196450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death.
    Amara N; Boveda S; Defaye P; Klug D; Treguer F; Amet D; Perier MC; Gras D; Algalarrondo V; Bouzeman A; Piot O; Deharo JC; Fauchier L; Babuty D; Bordachar P; Sadoul N; Marijon E; Leclercq C;
    Europace; 2018 Jan; 20(1):65-72. PubMed ID: 28082419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of cardiac resynchronization therapy with the incidence of appropriate implantable cardiac defibrillator therapies in ischaemic and non-ischaemic cardiomyopathy.
    Loughlin G; Avila P; Martinez-Ferrer JB; Alzueta J; Vinolas X; Brugada J; Arizon JM; Fernandez-Lozano I; García-Campo E; Basterra N; Fernandez De La Concha J; Arenal A
    Europace; 2017 Nov; 19(11):1818-1825. PubMed ID: 28339565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambulatory blood pressure monitoring, 2D-echo and clinical variables relating to cardiac events in ischaemic cardiomyopathy following cardioverter-defibrillator implantation.
    Antonini L; Pasceri V; Mollica C; Ficili S; Poti G; Aquilani S; Santini M; La Rocca S
    J Cardiovasc Med (Hagerstown); 2011 May; 12(5):334-9. PubMed ID: 21487343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early mortality in prophylactic implantable cardioverter-defibrillator recipients: development and validation of a clinical risk score.
    Kraaier K; Scholten MF; Tijssen JG; Theuns DA; Jordaens LJ; Wilde AA; van Dessel PF
    Europace; 2014 Jan; 16(1):40-6. PubMed ID: 23918791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES risk score.
    van Rees JB; Borleffs CJ; van Welsenes GH; van der Velde ET; Bax JJ; van Erven L; Putter H; van der Bom JG; Schalij MJ
    Heart; 2012 Jun; 98(11):872-7. PubMed ID: 22581736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of electrophysiology study in risk stratification of sudden cardiac death.
    Thomas KE; Josephson ME
    Prog Cardiovasc Dis; 2008; 51(2):97-105. PubMed ID: 18774009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
    Hess PL; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton A; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders G
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2):179-86. PubMed ID: 25669833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiology testing for risk stratification of patients with ischaemic cardiomyopathy: a call for action.
    Katritsis DG; Zografos T; Hindricks G
    Europace; 2018 Sep; 20(FI2):f148-f152. PubMed ID: 29236981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denervated Myocardium Is Preferentially Associated With Sudden Cardiac Arrest in Ischemic Cardiomyopathy: A Pilot Competing Risks Analysis of Cause-Specific Mortality.
    Fallavollita JA; Dare JD; Carter RL; Baldwa S; Canty JM
    Circ Cardiovasc Imaging; 2017 Aug; 10(8):. PubMed ID: 28794139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in predictors of implantable cardioverter-defibrillator therapies in patients with ischaemic and non-ischaemic cardiomyopathies.
    Darma A; Nedios S; Kosiuk J; Richter S; Doering M; Arya A; Rolf S; Sommer P; Hindricks G; Bollmann A
    Europace; 2016 Mar; 18(3):405-12. PubMed ID: 26056190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
    Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of ICD programming on inappropriate and appropriate ICD Therapies in ischemic and nonischemic cardiomyopathy: the MADIT-RIT trial.
    Sedláček K; Ruwald AC; Kutyifa V; McNitt S; Thomsen PEB; Klein H; Stockburger M; Wichterle D; Merkely B; DE LA Concha JF; Swissa M; Zareba W; Moss AJ; Kautzner J; Ruwald MH;
    J Cardiovasc Electrophysiol; 2015 Apr; 26(4):424-433. PubMed ID: 25546486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable defibrillators in ischaemic cardiomyopathy: should women be treated differently to men?
    Leung DY
    Heart; 2014 Feb; 100(3):190-1. PubMed ID: 24270745
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness of implantable cardioverter-defibrillators.
    Sanders GD; Hlatky MA; Owens DK
    N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.